Clearfield CEO Cheri Beranek to retire March 31, 2027; board begins successor search
Clearfield, Inc.
Beranek remains President and CEO until the earlier of a successor's appointment or March 31, 2027, then becomes President and CEO Emeritus in a non-executive, non-director role.
Transition agreement dated Oct. 15, 2026 keeps her base salary at $483,000 and benefits unchanged; no future equity awards; 2027 incentive bonus set at 100% of salary and not prorated.
March 31, 2027 departure will be treated as termination without Cause, subject to a general release, preserving severance benefits under her 2008 employment agreement.
Board Chair Catherine T. Kelly said the board will consider external and internal candidates and will use a nationally recognized search firm.
Clearfield expects fiscal 2026 fourth-quarter and full-year results in line with guidance given Aug. 5, 2026; results are due after market close on Nov. 10, 2026.
On October 15, 2026, Clearfield, Inc. (the “Company”) and Cheryl Beranek, President and Chief Executive Officer of the Company, entered into a transition agreement (the “Transition Agreement”), to facilitate Ms. Beranek’s retirement on March 31, 2027 and the smooth transition to a successor President and Chief Executive Officer.
Key facts
Extracted from this filing and checked against the source text.
Executive changeSEC 8-K Item 5.02confidence 0.95
Cheryl Beranek departed as President and Chief Executive Officer at Clearfield, Inc..
Action
retirement
Role
President and Chief Executive Officer
Exact text from the filing
On October 15, 2026, Clearfield, Inc. (the “Company”) and Cheryl Beranek, President and Chief Executive Officer of the Company, entered into a transition agreement (the “Transition Agreement”), to facilitate Ms. Beranek’s retirement on March 31, 2027 and the smooth transition to a successor President and Chief Executive Officer.
This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.